The Pharma Data

DECEMBER 8, 2020

Laying down a new track for RNA processing, Remix launched with $81 million in financing. Funds will be used to support development of the REMaster technology platform and advance the company’s pipeline of RNA processing targeted therapeutics as well. “As Pear Therapeutics.

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

AUGUST 16, 2021

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Broad Institute

OCTOBER 4, 2023

Today, scientists use such reactions to produce the customizable DNA and RNA molecules that enable genetic sequencing, drug and vaccine development, pathogen tests, cancer diagnostics, and more. Wang concluded her presentation by expressing gratitude to Merkin. I’m really thankful for the support of the Merkin Fellowship,” she said. “It

DNA 52

DNA RNA Science Protein Expression 52

Codon

APRIL 9, 2023

Small snippets of double-stranded RNA were sprayed onto hot pepper plants to control a pest, called Frankliniella occidentalis. The RNA strands shut down a specific gene in the insects, and killed half after 7 days. RNA may offer a safer form of pest control in the future. The new sequences might help de-extinction efforts.

Therapies 52

Therapies RNA Engineering Vaccine 52

Broad Institute

AUGUST 24, 2022

Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors. These data suggest a multi-omics predictor for chemotherapy response is within reach.

DNA 52

DNA Protein Expression Treatment Protein Production 52

The Pharma Data

JANUARY 10, 2021

The drug is an RNA interference (RNAi) therapeutic. The study hit the mark on its primary biological endpoint of micro-dystrophin protein expression. The trial met primary and both secondary endpoints at nine months.

Clinical Trials 52

Clinical Trials Trials FDA Vaccine 52

Alta Sciences

APRIL 17, 2024

Oligonucleotide-Based Techniques Most oligonucleotide therapies act through antisense mechanisms and are directed against various RNA species. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

Conversations in Drug Development Trends

MAY 30, 2024

This approach is facilitated by developing ASOs and RNA interference (RNAi) therapies, which target the various molecular and genetic mechanisms contributing to ALS pathophysiology and disease progression.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

The Pharma Data

SEPTEMBER 22, 2020

The company’s commitment to SMA extends beyond gene therapy to branaplam (LMI070), an oral, once-weekly RNA splicing modulator also currently under development, to expand the treatment options for SMA patients. .

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52